Trial Profile
LDL cholesterol-lowering and circulating PCSK9 levels: comparison with doubling dose of atorvastatin and ezetimibe combination following standard-dose atorvastatin non-response
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2012
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Ezetimibe
- Indications Hypercholesterolaemia
- Focus Biomarker; Therapeutic Use
- 06 Sep 2012 New trial record